Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial
-
Published:2022-04-05
Issue:3
Volume:86
Page:1399-1413
-
ISSN:1387-2877
-
Container-title:Journal of Alzheimer's Disease
-
language:
-
Short-container-title:JAD
Author:
Hua Xue1, Church Kevin1, Walker William1, L’Hostis Philippe2, Viardot Geoffrey2, Danjou Philippe3, Hendrix Suzanne4, Moebius Hans J.1
Affiliation:
1. Athira Pharma, Inc., Bothell, WA, USA 2. Core Lab, Drug Evaluation and Pharmacology Research, Biotrial, Rennes, France 3. Phase 1 Unit, Drug Evaluation and Pharmacology Research, Biotrial, Newark, NJ, USA 4. Pentara Corporation, Millcreek, UT, USA
Abstract
Background: Fosgonimeton (ATH-1017) is being developed as a first-in-class regenerative therapy for people with Alzheimer’s disease (AD) and dementia; potentially improving dementia symptoms and altering disease progression by reversing synaptic disconnection and neuronal loss. Objective: This randomized, double-blind, placebo-controlled phase I trial (NCT03298672) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of fosgonimeton. Methods: Fosgonimeton was administered once daily via subcutaneous injection to 88 subjects. The single ascending dose study enrolled healthy young male subjects (n = 48; age, 33.4±6.3 years; dose, 2, 6, 20, 40, 60, or 90 mg); the multiple ascending dose study enrolled healthy elderly subjects (n = 29; age, 63.8±4.0 years; dose, 20, 40, 60, or 80 mg; 9-day duration); and the fixed-dose study enrolled AD subjects (n = 11; age, 69.2±7.1 years; dose, 40 mg; 9-day duration). Quantitative electroencephalogram (qEEG) and event-related potential (ERP) P300 measured neurophysiological signals following fosgonimeton treatment, supporting brain penetration and target engagement. Results: Fosgonimeton and placebo were shown to be safe and well-tolerated across all doses. Pharmacokinetic results for fosgonimeton were dose-proportional, with no sex effect or accumulation over 9 days. The main effect of fosgonimeton on qEEG was acute and sustained gamma power induction. In AD subjects, there was a significant effect toward ERP P300 latency normalization compared with placebo (p = 0.027; n = 7 at 40 mg fosgonimeton versus n = 4 placebo). Conclusion: These results support the continued development of fosgonimeton as a novel therapeutic for people with AD and dementia. The fast-onset normalization of ERP P300 latency in AD subjects suggests enhancement of synaptic function and potential procognitive effects.
Subject
Psychiatry and Mental health,Geriatrics and Gerontology,Clinical Psychology,General Medicine,General Neuroscience
Reference58 articles.
1. Alzheimer’s disease;Scheltens;Lancet,2021 2. Caregiver burden characterization in patients with Alzheimer’s disease or vascular dementia;D’Onofrio;Int J Geriatr Psychiatry,2015 3. Survival in memory clinic cohort is short, even in young-onset dementia;Rhodius-Meester;J Neurol Neurosurg Psychiatry,2019 4. 2021 Alzheimer’s disease facts and figures;Alzheimer’s Association;Alzheimers Dement,2021 5. Prince M , Wimo A , Guerchet M , Ali G , Wu Y , Prina M (2015) World Alzheimer Report 2015. The global impact of dementia: An analysis of prevalence, incidence, cost and trends.. Alzheimer’s Disease International, London.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|